Shares of Bioanalytical Systems (BASI) opened at $1.90 on Friday. The company has a market cap of $16.16, a price-to-earnings ratio of -11.18 and a beta of 0.94. The company has a current ratio of 0.69, a quick ratio of 0.57 and a debt-to-equity ratio of 0.57. Bioanalytical Systems has a 52-week low of $0.81 and a 52-week high of $2.95.
An institutional investor recently raised its position in Bioanalytical Systems stock. Vanguard Group Inc. boosted its position in shares of Bioanalytical Systems, Inc. (NASDAQ:BASI) by 12.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 112,296 shares of the company’s stock after buying an additional 12,300 shares during the quarter. Vanguard Group Inc. owned approximately 1.37% of Bioanalytical Systems worth $190,000 at the end of the most recent reporting period. 5.14% of the stock is owned by hedge funds and other institutional investors.
Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.
Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with MarketBeat.com's FREE daily email newsletter.